Advancements in the Treatment of Cystic Fibrosis: From Targeting Symptoms to Targeting Genes

ACPE UAN #:  0233-0000-17-032-H01-P

Release Date: March 29, 2017

Expiration Date:  March 29, 2020

Activity Type:    Knowledge-based

Contact Hours:  1.25

Activity Fee:  Member:  $15        Non-Member: $30

Target Audience: Pharmacists who practice in managed care settings.

Activity Overview

Cystic fibrosis (CF) presents an enormous clinical and emotional burden for patients and caregivers, and more recently has become a striking economic burden to the healthcare system. Although CF affects only a small proportion of the overall population, the cost associated with its management has increased dramatically, with newer therapies costing upwards of $325,000 per year. As there is no cure for CF, current management strategies have focused on preserving lung function, reducing pulmonary exacerbations and improving nutritional status. Recently, there has been an emergence of novel genotype-, mutation-specific therapies that target the underlying defects in CF by modifying the cystic ­ fibrosis transmembrane conductance regulator proteins. This session will provide pharmacists an overview of the disease state of CF, current management strategies recommended to improve the outcomes for CF patients as well as inform payers of specialty drugs within the pharmaceutical pipeline for the management of this disease. 

Learning Objectives:  

At the completion of this activity, participants should be able to:

1. Explain the clinical manifestations of cystic ­ fibrosis (CF).

2. Recognize key components of pharmacologic therapy within the current treatment guidelines.

3. Discuss the emergence of novel therapies for CF and identify at least one drug in the pipeline.

4. Summarize the effects of newer therapeutic options on patient outcomes and their potential cost  impacts on health plans.

5. Discuss management strategies employed by health plans and pharmacy bene­fit managers to manage the costs associated with the treatment of CF. 

Schedule of Educational Activity

This activity consists of an audio recording, pre-test assessment questions (not required to pass or continue), post-test questions (required to pass with a score of 70% or higher) and a specific activity evaluation. 

CPE Requirements:   

Participants should claim continuing pharmacy education (CPE) credit for this home study activity only if they have not claimed credit for the live activity presented at the AMCP Annual Meeting 2017. 

CPE credit will be processed through the AMCP Learn portal and reported directly to CPE Monitor.  Please allow 72 hours for processing and posting in your NABP account. 

To receive credit for an online activity you must:

  • Review the full content of the activity.
  • Successfully complete the post-test (required to pass with a score of 70% or higher, it may be taken a maximum of three times).
  • Complete a specific activity evaluation.

System Technical Requirements/Viewing Requirements: System Requirements Courses and learning activities are delivered via your Web browser and Acrobat PDF. For all activities, you should have a basic comfort level using a computer and navigating web sites.  View the minimum technical and system requirements for continuing education online learning activities.

As an accredited provider, AMCP strictly adheres to the ACPE Standards for Commercial Support and other relevant guidelines and standards to ensure the independence of continuing pharmacy education (CPE) activities.  It is AMCP’s intent that all CPE activities be independent, objective, balanced, evidence-based and free of any commercial bias.


Kimberly Lenz, PharmD | Clinical Pharmacy Manager, MassHealth | University of Massachusetts Medical School | Quincy, Massachusetts

Credit Information

Activity Number Credit Amount Accreditation Period
ACPE UAN #0233-0000-17-032-H01-P 1.25 Contact Hours March 29, 2017 - March 29, 2020